[HTML][HTML] Treatment of gastric cancer

M Orditura, G Galizia, V Sforza… - World journal of …, 2014 - ncbi.nlm.nih.gov
The authors focused on the current surgical treatment of resectable gastric cancer, and
significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4 th …

Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives

J Ventriglia, I Paciolla, C Pisano, SC Cecere… - Cancer treatment …, 2017 - Elsevier
The tumors of the female genital tract represent a leading cause of morbidity and mortality
among women worldwide. Substantial progresses have been made in ovarian cancer, with …

Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs

A Diana, E Franzese, S Centonze, F Carlino… - Current oncology …, 2018 - Springer
Abstract Purpose of Review Triple-negative breast cancer (TNBC) accounts for 15–20% of
diagnosed breast tumours, with higher incidence in young and African-American women …

[HTML][HTML] Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis

M Orditura, G Galizia, A Diana, C Saccone, L Cobellis… - ESMO open, 2016 - Elsevier
Objective To assess the correlation between presurgery neutrophil to lymphocyte ratio
(NLR) and distant metastasis-free survival (DMFS) in patients with early breast cancer …

[HTML][HTML] Pancreatic neuroendocrine tumors: Nosography, management and treatment

M Orditura, A Petrillo, J Ventriglia, A Diana… - International Journal of …, 2016 - Elsevier
Pancreatic neuroendocrine tumors (pNETs) represent about 7% of all NETs, 8.7% of
gastroenteropancreatic NETs (GEP-NETs) and 1–2% of all pancreatic neoplasms. In the last …

[HTML][HTML] NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

F De Vita, J Ventriglia, A Febbraro, MM Laterza… - Bmc Cancer, 2016 - Springer
Background Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a
randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed …

Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab. A multicenter …

A Farolfi, M Petrone, E Scarpi, V Gallà, F Greco… - Targeted …, 2018 - Springer
Background The variability in progression-free survival (PFS) and overall survival (OS)
among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict …

Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the RAMoss study

M Di Bartolomeo, M Niger, G Tirino, A Petrillo… - Targeted Oncology, 2018 - Springer
Background Ramucirumab—alone or combined with paclitaxel—represents one of the main
options for patients failing first-line treatment for advanced gastric cancer. Objective The …

[HTML][HTML] Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer

A Passarelli, C Pisano, SC Cecere… - Frontiers in …, 2022 - frontiersin.org
Immunotherapy is acquiring a primary role in treating endometrial cancer (EC) with a
relevant benefit for many patients. Regardless, patients progressing during immunotherapy …

[HTML][HTML] Clinical management of advanced gastric cancer: the role of new molecular drugs

F De Vita, N Di Martino, A Fabozzi… - World Journal of …, 2014 - ncbi.nlm.nih.gov
Gastric cancer is the fourth most common malignant neoplasm and the second leading
cause of death for cancer in Western countries with more than 20000 new cases yearly …